US: CKDXF - Opthea Ltd

Rentabilität für sechs Monate: +51.72%
Dividendenrendite: 0.00%

Aktionsplan Opthea Ltd

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen Opthea Ltd

Opthea Limited, a clinical-stage biopharmaceutical company, develops and commercializes drugs for eye diseases in Australia and the United States. Its development activities are based on the intellectual property portfolio covering vascular endothelial growth factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.

weitere details
The company's lead product candidate is sozinibercept (OPT-302), a biologic drug in Phase 3 clinical trials designed to inhibit VEGF-C and VEGF-D and complement VEGF-A inhibitors for the treatment of wet age-related macular degeneration and diabetic macular edema. It serves the biotechnology and healthcare industries. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is headquartered in South Yarra, Australia.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://opthea.com
Цена ао 0.44
Preisänderung pro Tag: 0% (0.44)
Preisänderung pro Woche: 0% (0.44)
Preisänderung pro Monat: 0% (0.44)
Preisänderung über 3 Monate: 0% (0.44)
Preisänderung über sechs Monate: +51.72% (0.29)
Preisänderung pro Jahr: +51.72% (0.29)
Preisänderung über 3 Jahre: -59.63% (1.09)
Preisänderung über 5 Jahre: -81.89% (2.43)
Preisänderung seit Jahresbeginn: 0% (0.44)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 1484.6 1
P/BV -2.44 0
P/E 0 0
EV/EBITDA -0.774 0
Gesamt: 2.75

Effizienz

Name Bedeutung Grad
ROA, % -130.72 0
ROE, % 520.65 10
Gesamt: 3.33

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0.59

Pflicht

Name Bedeutung Grad
Debt/EBITDA -0.7108 10
Gesamt: 9.8

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 107.95 10
Rentabilität Ebitda, % 1044.01 10
Rentabilität EPS, % 738.93 10
Gesamt: 10
Weitere Details

Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Dr. Frederic Guerard M.S., Pharm.D. Chief Executive Officer 1972 (53 Jahr)
Dr. Megan Baldwin M.A.I.C.D., MAICD, Ph.D. Founder, Chief Innovation Officer & Executive Director 1975 (50 Jahre)
Ms. Karen Adams CPA VP of Finance & Company Secretary 1971 (54 Jahr)
Mr. Daniel E. Geffken M.B.A. Interim CFO 1957 (68 Jahre)
Mr. Kevin Bitter VP of Strategy & Corporate Development 1992 (33 Jahr)
Ms. Sarika Gulhar Ph.D. Executive Director of Human Resources
Dr. Michael Gerometta Ph.D. Head of Chemistry, Manufacturing & Controls Development 1965 (60 Jahre)
Dr. Kenneth Sall Chief Medical Officer
Dr. Fang Li Ph.D. Senior Vice President of Regulatory Affairs 1964 (61 Jahr)
Dr. Julie Clark M.D., M.S. Senior Vice President of Clinical Development 1975 (50 Jahre)

Adresse: Australia, South Yarra, 650 Chapel Street - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://opthea.com